Summarized by Masters of Longevity from Longevity Technology.
Reports compare two Lilly strategies for treating obesity with type 2 diabetes, highlighting differing weight loss and tolerability outcomes across trials.
Key Takeaways
- Retatrutide produced up to 20.8% weight loss under an efficacy estimand and 18.8% under a treatment regimen estimand.
- EloraTZP, an amylin plus GLP-1 combination, achieved up to 23.3% weight loss in a Phase 2 diabetes population.
- Discontinuation rates varied widely: retatrutide had 4–12% quits across doses while eloraTZP saw 10.8–27.0% quits at higher doses.
